Valor pronóstico del recuento de leucocitos y plaquetas, en tumores testiculares de células germinales

Herraiz-Raya, L.; Moreillo-Vicente, L.; Martínez-Ruiz, J.; Agustí-Martínez, A.; Fernández-Anguita, P.J.; Esper-Rueda, J.A.; Salce-Marte, L.; Armas-Alvarez, Azucena Lirio; Migallón, I. Díaz de Mera-Sánchez; Martínez-Alfaro, C.; Giménez-Bachs, José M.; Donate-Moreno, María J.; Salinas-Sánchez, Antonio S.

doi:10.1016/j.acuro.2019.02.002

Cited by 8 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, an increased NLR and elevated absolute platelet and absolute neutrophil counts were associated with advanced stages of disease (stage II–III). Absolute neutrophil counts also correlated with more frequent progression of disease and mortality ( 26 ). Interestingly, Chovanec et al performed a combinatorial survival analysis involving the systemic immune-inflammation index (SII) based on platelet, neutrophil and lymphocyte counts and PD-L1 expression on tumor infiltrating lymphocytes (TILs).…”

Section: Rationale For Immunotherapy In Testicular Cancermentioning

confidence: 99%

Immunotherapy in Testicular Germ Cell Tumors

et al. 2020

View full text Add to dashboard Cite

Testicular germ cell tumors (TGCTs) are malignancies with very high curative potential even in metastatic settings, mainly due to the introduction of cisplatin in the treatment of this disease. However, in a group of patients with cisplatin-refractory disease or with progressive disease despite high-dose salvage chemotherapy treatment, the prognosis is typically dismal. The triple combination of gemcitabine, oxaliplatin, and paclitaxel (GOP) has reasonable efficacy and is considered to be standard care for this group of patients. It remains to be seen, however, whether refractory TGCTs may represent a potential target for immune checkpoint inhibition. This review will focus on the rationale of the use of immunotherapy for platinum-refractory TGCTs and summarize data reporting experiences with immune checkpoint inhibitor treatment for this malignancy.

show abstract

Section: Rationale For Immunotherapy In Testicular Cancermentioning

confidence: 99%

Immunotherapy in Testicular Germ Cell Tumors

et al. 2020

View full text Add to dashboard Cite

show abstract

Low-cord orchidectomy for testicular cancer: what would be different?

Sarıkaya,

Şen,

Yörükoğlu

et al. 2024

World J Urol

View full text Add to dashboard Cite

Introduction High cord radical orchidectomy (HRCO) is accepted as the standard surgical approach in testicular cancer, however low cord orchidectomy (LCRO) can reduce the morbidity of operation without worsening the oncological outcomes. Methods We retrospectively re-examined the specimens of men to determine the level of spermatic cord invasion (SCI). Men who had proximal SCI with negative surgical margins after HRCO were assumed to have de-novo residual tumour if LCRO was performed. Others were assumed as oncologically similar. We examined the relation between pre-operative variables and SCI and proximal SCI to determine whether prediction of proximal SCI is possible. Results 196 patients were included. 22 (11%) had SCI and ten (5%) had proximal SCI. Four patients with proximal SCI had positive surgical margins even after HRCO and didn’t require additional local treatment. Six patients were assumed to have de-novo residual tumour if LCRO was performed. All six patients were metastatic and had systemic chemotherapy. High platelet count, tumour size, N stage, S stage and M stage were all significantly related with both SCI and proximal SCI (p < 0.05). Conclusion Due to low probability of SCI, we think LCRO can safely be performed to reduce morbidity in Stage 1 patients. Although there is a risk for residual tumour in Stage 2–3 patients, currently there is no data that residual tumour would impair the success of systemic chemotherapy. Therefore we can not assume that these patients would be negatively affected. Pre-operative data can be useful to predict the presence of proximal SCI and select appropriate patients for LCRO.

show abstract